HK1117402A1 - Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders - Google Patents

Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders

Info

Publication number
HK1117402A1
HK1117402A1 HK08108222.5A HK08108222A HK1117402A1 HK 1117402 A1 HK1117402 A1 HK 1117402A1 HK 08108222 A HK08108222 A HK 08108222A HK 1117402 A1 HK1117402 A1 HK 1117402A1
Authority
HK
Hong Kong
Prior art keywords
methylimidazol
pyridine
methyl
sleep disorders
treating sleep
Prior art date
Application number
HK08108222.5A
Other languages
English (en)
Inventor
Christian N Lavedan
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of HK1117402A1 publication Critical patent/HK1117402A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08108222.5A 2005-07-29 2008-07-24 Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders HK1117402A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70360405P 2005-07-29 2005-07-29
US73253605P 2005-11-02 2005-11-02
PCT/US2006/029112 WO2007016203A1 (fr) 2005-07-29 2006-07-26 Procede permettant d'ameliorer l'etat de veille

Publications (1)

Publication Number Publication Date
HK1117402A1 true HK1117402A1 (en) 2009-01-16

Family

ID=37708941

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08108222.5A HK1117402A1 (en) 2005-07-29 2008-07-24 Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders

Country Status (12)

Country Link
US (1) US20080280954A1 (fr)
EP (1) EP1919477B1 (fr)
JP (1) JP5017268B2 (fr)
KR (2) KR101146807B1 (fr)
AU (1) AU2006275824B2 (fr)
BR (1) BRPI0614701A2 (fr)
CA (1) CA2616177C (fr)
ES (1) ES2388876T3 (fr)
HK (1) HK1117402A1 (fr)
NO (1) NO20080993L (fr)
NZ (1) NZ565763A (fr)
WO (1) WO2007016203A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095523A2 (fr) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. compositions DE DOSAGE STABLES D'IMIDAZOLYLALKYLPYRIDINES
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
WO2009097414A1 (fr) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Utilisation d'imidazolylalkyl-pyridines pour le traitement de troubles addictifs
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
SI2806863T1 (sl) 2012-01-26 2017-12-29 Vanda Pharmaceuticals Inc. Zdravljenje motenj cirkadianega ritma
WO2013188806A1 (fr) 2012-06-14 2013-12-19 The Regents Of The University Of Michigan Traitement d'apnée du sommeil
CN110200958A (zh) 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
CN103087019B (zh) * 2013-02-06 2015-02-04 济南志合医药科技有限公司 一种他司美琼的制备方法
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DE4131584A1 (de) * 1991-09-23 1993-03-25 Sandoz Ag Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika
US5635521A (en) * 1991-09-23 1997-06-03 Sandoz Ltd. Imidazolylmethyl-pyridines
EP0885210B2 (fr) 1996-03-08 2008-06-18 Takeda Pharmaceutical Company Limited Composés tricycliques avec une affinité de liaison pour des recepteurs de la melatonine, leur production et leur utilisation
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
GB0009037D0 (en) 2000-04-13 2000-05-31 Novartis Ag Organic compounds
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US7528172B2 (en) 2003-01-21 2009-05-05 The Cooper Health System, Inc. Compositions and methods for improving recovery after general anesthesia

Also Published As

Publication number Publication date
KR20110011748A (ko) 2011-02-08
US20080280954A1 (en) 2008-11-13
CA2616177A1 (fr) 2007-02-08
KR101146807B1 (ko) 2012-05-21
EP1919477B1 (fr) 2012-07-11
BRPI0614701A2 (pt) 2011-04-12
KR101187461B1 (ko) 2012-10-02
EP1919477A1 (fr) 2008-05-14
AU2006275824A1 (en) 2007-02-08
WO2007016203A1 (fr) 2007-02-08
ES2388876T3 (es) 2012-10-19
NZ565763A (en) 2010-12-24
NO20080993L (no) 2008-02-25
JP2009502945A (ja) 2009-01-29
KR20080033322A (ko) 2008-04-16
AU2006275824B2 (en) 2010-12-16
JP5017268B2 (ja) 2012-09-05
CA2616177C (fr) 2012-05-01
EP1919477A4 (fr) 2009-03-18

Similar Documents

Publication Publication Date Title
HK1117402A1 (en) Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PL1701944T3 (pl) (2-Amino-podstawione)-4-arylopirymidyny i związki pokrewne, użyteczne do leczenia chorób zapalnych
ZA200804198B (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL187302A0 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ZA200806457B (en) Use of 4-imidazole derivatives for CNS disorders
AU2008281877A8 (en) The use of benzamide derivatives for the treatment of CNS disorders
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
HK1133426A1 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper- proliferative disorders and diseases associated with angiogenesis
EP1957077A4 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
ZA200708591B (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
EP1901733A4 (fr) Utilisation d'huperzine pour des pathologies
IL187739A0 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
EP2139475A4 (fr) Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
PL1793783T3 (pl) Sposób wytwarzania jednorazowych wyrobów chłonnych
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0604780D0 (en) Use of substituted piperazine compounds for the treatment of food related disorders
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160726